Allergan financial report

Directors’ Report
PRINCIPAL ACTIVITIES

The company is a speciality biopharmaceutical and medical device firm which commercialises products for the neurosciences, ophthalmology, medical aesthetics and other speciality markets.

Allergan is dedicated to delivering value to its customers, improving people’s lives and satisfying unmet medical needs.

BUSINESS REVIEW – Year ended December 31st 2007

The balance sheet indicates the company’s financial position at the end of the year, in net asset terms, has improved from restated net assets of £9,466,000 in 2006 to £13,258,000 in 2007.

Charitable donations in the year amounted to £34,797. No political donations were made.

RESULTS
The company’s turnover has increased by a total of 34 per cent from £38,509,000 in 2006 to £51,536,000 in 2007. Profit after tax has improved from a restated profit of £1,750,000 to £2,541,000.

Employees
OFFICERS OF THE COMPANY

Directors who served during the year and to the date of the report were:

David Endicott
Sue-Jean Lin (resigned March 2nd 2007)
Carole Chappell
David Trevor
Judy Williams (resigned January 2nd 2007)
Vivid Sehgal (appointed March 7th 2007)
Thim Engal (appointed March 7th 2007)

Management remain confident about Allergan’s future prospects.
The directors do not recommend the payment of a dividend (2006 – nil).

Zenopa sourced data on Allergan:

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercialising innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential – to see more clearly, move more freely, express themselves more fully.

Its focus fosters deep engagement with medical specialists and Allergan makes it its business to listen closely to their needs so that together it can advance patient care. Allergan combines this strategic focus with a diversified approach that enables it to follow its research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, it brings scientific excellence and rigor to deliver leading products that improve patient outcomes. And, Allergan goes above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. Allergan knows it is successful when doctors and patients place their trust in its products and the company, when its employees excel and when its efforts make a meaningful difference in the lives of the patients and communities Allergan serves.

Allergan are pleased to offer a number of leading products, including: BOTOX (Botulinum Toxin Type A), RESTASIS (cyclosporine ophthalmic emulsion) 0.05 per cent, LUMIGAN (bimatoprost ophthalmic solution) 0.03 per cent, BOTOX Cosmetic (Botulinum Toxin Type A), the JUVEDERM family of dermal fillers, and the LAP-BAND Adjustable Gastric Banding System. Throughout its website you can learn more about these and its full portfolio of products.